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Atherothrombosis, the pathology underlying numerous cardiovascular diseases, is a
major cause of death globally. Hyperactive blood platelets play a key role in the
atherothrombotic process through the release of inflammatory mediators and formation
of thrombi. In healthy blood vessels, excessive platelet activation is restricted by
endothelial-derived prostacyclin (PGI2) through cyclic adenosine-50-monophosphate
(cAMP) and protein kinase A (PKA)-dependent mechanisms. Elevation in intracellular
cAMP is associated with the control of a number of distinct platelet functions including
actin polymerisation, granule secretion, calcium mobilization and integrin activation.
Unfortunately, in atherosclerotic disease the protective effects of cAMP are compromised,
whichmay contribute to pathological thrombosis. The cAMP signaling network in platelets
is highly complex with the presence of multiple isoforms of adenylyl cyclase (AC), PKA,
and phosphodiesterases (PDEs). However, a precise understanding of the relationship
between specific AC, PKA, and PDE isoforms, and how individual signaling substrates
are targeted to control distinct platelet functions is still lacking. In other cells types,
compartmentalisation of cAMP signaling has emerged as a key mechanism to allow
precise control of specific cell functions. A-kinase anchoring proteins (AKAPs) play an
important role in this spatiotemporal regulation of cAMP signaling networks. Evidence of
AKAP-mediated compartmentalisation of cAMP signaling in blood platelets has begun to
emerge and is providing new insights into the regulation of platelet function. Dissecting
the mechanisms that allow cAMP to control excessive platelet activity without preventing
effective haemostasis may unleash the possibility of therapeutic targeting of the pathway
to control unwanted platelet activity.
Keywords: platelets, adenylyl cyclase, cAMP, A-kinase anchoring proteins, protein kinase A
INTRODUCTION
Blood platelets play a key role in haemostasis through binding to sites of vascular injury to
form a primary haemostatic plug. However, uncontrolled platelet activation is intimately linked to
thrombotic events associated with the rupture of atherosclerotic plaques. Controlling inappropriate
platelet activation is critical to protecting against thrombotic episodes. Primary inhibitory
mechanisms are mediated by endothelial derived-nitric oxide (NO) and prostacyclin (PGI2),
which stimulate soluble guanylyl cyclase (sGC) and adenylyl cyclase (AC) leading to activation
of cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP)-
mediated signaling pathways, respectively (Smolenski, 2012). cAMP/cGMP-dependent protein
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kinases phosphorylate target proteins that are associated with
controlling platelet activation while multiple phosphodiesterases
(PDEs) hydrolyse cyclic nucleotides to terminate signaling.
The cAMP and cGMP signaling pathways have overlapping
target specificity, but also synergise indicating diversity in
target selection. In many cell types the enzymes that generate,
propagate and terminate cAMP signaling are organized into
restricted microdomains that focus the activity of the cAMP
signaling cascade to specific substrates (Tasken and Aandahl,
2004; Scott and Pawson, 2009; Stangherlin and Zaccolo, 2012).
This compartmentalisation of cAMP signaling allows stimulus-
specific control of distinct cell functions. Given the central
importance of cAMP signaling to the control of platelet function,
surprisingly little is known about the molecular mechanisms that
coordinate the synthesis and hydrolysis of cAMP, the precise
molecular targets of cAMP signaling and how these targets
contribute to the control of specific platelet functions. In this
perspective article, we provide an overview of cAMP signaling and
examine emerging concepts of compartmentalization in platelets.
THE cAMP SIGNALING SYSTEM
IN PLATELETS
The binding of PGI2, prostaglandin E1 and adenosine to their
receptors on platelets leads to the elevation of intracellular cAMP
through the activation of AC. While there are nine membrane
bound isoforms of AC, human platelets express only AC3 and
AC5/6 (Rowley et al., 2011; Burkhart et al., 2012; Cooper and
Tabbasum, 2014). The roles of these individual AC isoforms
and whether they are linked to specific receptors or stimuli are
unknown. Increased cAMP leads to the activation of protein
kinase A (PKA), the foremost effector of cAMP signaling in
platelets. The holoenzyme of PKA is an inactive heterotetramer
composed of two regulatory (R) and two catalytic (C) subunits.
Platelets express all the known isoforms of the regulatory and
catalytic subunits (RIa, RIb, RIIa, RIIb, Ca, Cb, and Cg) (Pidoux
and Taskén, 2010; Burkhart et al., 2012), indicating that platelets
likely possess multiple variations of the two PKA subtypes,
PKA-I and PKA-II, which have distinct biochemical properties.
The binding of four cAMP molecules to their binding sites on
PKA, result in a conformational change unleashing the catalytic
subunit and consequently the phosphorylation of adjacent protein
substrates. To date sixteen substrates have been characterized in
platelets, although a recent proteomic study suggests that over 100
substrates may be present (Beck et al., 2014). These substrates
can be categorized into proteins involved in regulating: (i) shape
change (actin polymerization), (ii) calcium signaling, or (iii)
integrin activation (Schwarz et al., 2001; Raslan and Naseem,
2014). The phosphorylation of these proteins by PKA is proposed
to be the primary mechanism by which prostacyclin modulate
platelet activation. As platelet pass through the circulation they
aremarginalized to the periphery of the vessel facilitating constant
exposure to endothelial-derivedPGI2. Therefore it is likely that the
default status of platelets in the circulation is one of elevated cAMP
and activated PKA, which maintains the cells in a quiescent state.
However, to facilitate platelet activation at sites of vascular injury
the inhibitory effects of basal cAMP signaling must be overcome.
Upon activation, platelets generate and release soluble factors that
act in a paracrine fashion to promote platelet activation through
the inhibition of cAMP signaling. Platelet-derived adenosine
diphosphate (ADP) inhibits AC activity through binding to
Gai-coupled P2Y12 that blocks cAMP synthesis. Simultaneously,
thrombin and thrombospondin-1 activate PDE3A, leading to
reduced intracellular cAMP (Gachet et al., 2006; Zhang and
Colman, 2007; Roberts et al., 2010). Together, these mechanisms
act to reduce the threshold for platelet activation and ensure
rapid recruitment of platelets to vascular lesions. An imbalance
in this dynamic system can have profound effects on platelets
function as exemplified by several recently identified congenital
disorders that affect cAMP production (Geet et al., 2009). A Gas
hypofunction mutation is associated with platelet hyperactivity
(Freson et al., 2009). Conversely, a Gas gain-of-functionmutation
is reported to lead to a trauma-related bleeding tendency (Freson
et al., 2003). Consistent with these observations, a recently
identified mutation in the gene encoding the catalytic subunit
of PKA leads to macrothrombocytopenia with the homozygous
patients showing a bleeding tendency (Manchev et al., 2014). The
control of cAMP signaling and therefore the phosphorylation of
key PKA substrates is mediated by both protein phosphatases
and several PDEs through the hydrolysis of cAMP into 50-AMP.
Platelets express two cAMP hydrolysing enzymes, PDE2A and
PDE3A (Dickinson et al., 1997; Schwarz et al., 2001; Rondina and
Weyrich, 2012). However, the phosphatases that dephosphorylate
PKA substrates are unknown. Thus, platelets possess a complex
cAMP signaling network that includes multiple isoforms of AC,
PKA and PDE (Figure 1A), but molecular control and integration
of this network is required to maintain the balance between
haemostasis and thrombosis.
SPATIOTEMPORAL REGULATION OF
cAMP SIGNALING—THE ROLE OF AKAPs
The spatiotemporal control of cAMP signaling is influenced
by the opposing functions of localized AC and PDE isozymes
and the scaffolding properties of A-kinase anchoring proteins
(AKAPs). The cAMP signal is conveyed through assembly of
macromolecules that constrain cAMP signaling to specific regions
in the cell. The formation of multiple cAMP signaling hubs where
individual isoforms of PKA interact with anchoring proteins
that focus PKA activity on specific substrates, allows the control
of specific biological functions in response to distinct stimuli
(Tasken and Aandahl, 2004; Scott and Pawson, 2009; Stangherlin
and Zaccolo, 2012). Early studies reported that PKA substrates
were specifically localized in distinct subcellular compartments
of blood platelets (El-Daher et al., 1997, 2000). Our own
studies support these observations with distinct phospho-PKA
substrates found in cytosolic and membrane fractions of platelets
(Figure 1B). Consistent with the detection of PKA substrates
in multiple cell compartments we found using both subcellular
fractionation and immunostaining experiments that PKA-I and
PKA-II are differentially localized in platelets. PKA-RI was found
primarily at the cell periphery, while PKA-RII was clustered
within the cytosol (Raslan et al., 2015). We found that membrane
lipid rafts allow for further compartmentalization of cAMP
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FIGURE 1 | (A) Model for the control of platelet function by cAMP signaling in platelets. Segregated pools of cAMP are formed by the individual isoforms of AC. The
cAMP generated may target individual PKA isoforms. AKAPs act to focus isoform specific PKA activity to individual substrates that are linked to distinct platelet
functions. The AKAPs may also act to localize PDE isoforms in manner that controls specific signaling events. (B) PKA substrates are differentially distributed and
targeted by PKA in an AKAP-dependent manner. Washed platelets (5  108/mL) were left untreated or pre-treated for 60 min with RIAD-Arg11 (2 mM) or stHt31
(2 mM), which target PKA-I and PKA-II specific AKAPs respectively, followed by PGI2 (50 nM) for 1 min. Platelets were lysed then subjected into subcellular
fractionation (20,000 g, 90 min at 4°C) to separate platelet membranes. Membrane and cytosol fractions (20 mg) were analyzed by SDS-PAGE and immunoblotting
using phosphoPKA substrate antibody and integrin b as a membrane marker. Blots are representative of three independent experiments. Membranes were visualized
using enhanced chemiluminescence. Red and blue arrows represent AKAP sensitive bands in membrane and cytosolic bands respectively.
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signaling in platelets. For example, a pool of AC isoform 5/6 and
PKA-I, but not PKA-II, are localized to these membrane micro-
domains in platelets where the rafts act to constrain PKA activity
(Raslan and Naseem, 2015). Thus, PKA signaling in platelets, like
T-cells, dendritic cells and cardiomyocytes is compartmentalized
to membrane fractions in close proximity to the site of cAMP
generation (Ruppelt et al., 2007; Delint-Ramirez et al., 2011;
Schillace et al., 2011; Burgers et al., 2012). The question then arises
as to how these cAMP signaling compartments are organized
and configured in platelets. An elegant study using a chemical
proteomic approach indicated the presence of localized and active
cAMP signaling nodes, which were dynamic in nature with PKA
activity changing within distinct signaling complexes in response
to platelet activation.The formation of these complexes was
attributed to the presence of several AKAPs, although the precise
composition of these complexes or how they were convened was
not extrapolated (Margarucci et al., 2011). AKAPs are structurally
diverse scaffolding proteins that interact with PKA and target it
to a specific subcellular compartment through a unique targeting
domain. All AKAPs possess a highly conserved PKA binding
domain. This is an amphipathic helix, which can bind to the
docking and dimerization domain (D/D domain) of the PKA
regulatory homodimer (Carr et al., 1991; Kinderman et al., 2006;
Sarma et al., 2010). While AKAPs specifically bind PKA, they can
act as hubs that coalesce other signaling components including
kinases, phosphatases, PDEs, ACs, and even receptors. The
assembly of such macromolecules act as signal switches that are
intricately regulated spatially and temporally by signal initiators
and terminators. Over fifty AKAPs have now been identified and
of these fifteen are potentially expressed in platelets (Margarucci
et al., 2011; Rowley et al., 2011; Burkhart et al., 2012). Given the
potential complexity within the cAMP signaling system, it is likely
that AKAPs play a key role in the control of platelet function by
cAMP (Figure 1A). Unfortunately, the study of AKAPs in platelets
has been limited by an inability to apply standard molecular
biology approaches used to characterize AKAPs in many other
cells. However, he development of cell permeable disruptor
peptides that mimic the sequence of the amphipathic helix of
the PKA binding domain and target PKA-AKAP interactions in
an isoform-specific manner has allowed us to begin examine
this hypothesis (Carlson et al., 2006; Gold et al., 2006; Zhang
et al., 2014). These peptides can displace PKA frommulti-protein
complexes formed by AKAPs allowing the functional relevance
of these AKAPs to be evaluated. Focusing on PKA-I we used RI-
anchoring disruptor peptide or RIAD-Arg11 to demonstrate that
a number of cAMP signaling events in platelets were dependent
on PKA-I-AKAP interactions (Carlson et al., 2006).Examining
PKA signaling events using immunoblotting following subcellular
fractionation, we were able to observe a decrease in the intensity
of PKA phosphorylation events after stimulating with PGI2 in
the presence of RIAD-Arg11 in both membrane and cytosolic
fractions when compared with PGI2 alone suggesting that PGI2
trigger PKA-I-specific signaling events that are AKAP-dependent
in platelets (Figure 1B). This was followed by a number of
specialized assays, including aggregation, secretion and spreading
to evaluate the role of PKA-I-AKAPs interactions in the inhibitory
effect of prostacyclin on platelet function (Figure 2). As expected
collagen-induced platelet aggregation was inhibited by PGI2, but
the inhibitory action was diminished significantly by the presence
of RIAD-Arg11 (Figure 2A). The secretion of dense granules is
a major factor in potentiating platelet aggregation in response to
collagen.Luminescence assays demonstrated that PGI2 abolished
the secretion of ATP from these granules in response to collagen,
but again the presence of RIAD-Arg11 reversed its inhibitory
effects (Figure 2B). Finally platelets were adhered to immobilized
collagen to induce a physiological spreading response. In response
to collagen, platelets extended filopodia and lamellipodium
consistent with spreading (Figure 2C). The presence of PGI2
prevented the spreading response without influencing the ability
of platelets to adhere. However, pre-treating platelets with RIAD-
Arg11, allowed platelets to adhere and spread on collagen.
Interestingly, in all assays, RIAD-Arg11 failed to cause a full
recovery from the inhibitory effects, with the remaining effects of
cAMP potentially caused by PKA-II, which would be insensitive
to the effects of RIAD.While the data produced using the peptides
should be interpreted with caution, our observations suggest
that PKA-I-AKAP interactions are required for optimal PGI2
inhibition of collagen-induced platelet activation and that PKA-I
and PKA-II have non-redundant roles in human platelets.
The signaling events driven by compartmentalisation of PKA
isoforms are finessed by the PDEs (Rondina and Weyrich, 2012).
Using FRET, Lissandron et al. (2006) demonstrated that distinct
pools of cAMP could be shaped by specifically localized PDE
isoforms (Lissandron et al., 2006; Stangherlin and Zaccolo, 2012).
While the subcellular localisation of platelet PDEs is not clear
there is evidence for potential non-redundant roles in controlling
cAMP signaling. Pharmacological inhibition of PDE2A resulted
in increased basal cAMP, while inhibition of PDE3A blocked
platelet aggregation, reduced Ca2+ mobilization and increased
vasodilator stimulated phosphoprotein (VASP) phosphorylation
(Feijge et al., 2004). These data suggest PDE2A and PDE3A play
non-redundant roles, whereby the former controls elevated cAMP
levels and the latter maintains a threshold of cAMP levels in
pools that control integrin activation and Ca2+ mobilization.
Interestingly, PKA has been shown to phosphorylate and activate
of PDE3A in platelets (Macphee et al., 1988; Hunter et al., 2009),
suggesting a feedback regulatory mechanism within platelets
to control cAMP signaling. The molecular composition of this
feedback regulatory complex is ill-defined, although preliminary
data in our laboratory suggests that phosphorylation of PDE3A
is performed by PKA-II in an AKAP-dependent manner (Law
and Naseem, unpublished). The localisation of PDE isoforms to
specific signaling complexes and PKA substrates is a key area for
further characterisation of cAMP signaling in platelets.
EVIDENCE OF FUNCTIONAL AKAPs
IN PLATELETS
The concept of isoform-specific PKA substrates in platelets that
are regulated by an AKAP is an attractive one, although evidence
for their functional roles is still lacking. PlateletAKAPs as reported
in proteomic and transcriptome studies include AKAP1, AKAP2,
AKAP7(g), AKAP9, AKAP10, AKAP11, AKAP13, moesin, ezrin,
Rab32, BIG2 (brefeldin-A-inhibited guanine-nucleotideexchange
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FIGURE 2 | Inhibition of platelet activity by prostacyclin (PGI2) requires PKA-I/AKAP interactions. (A)Washed platelets (2.5  108/ml) were left untreated or
pre-incubated with RIAD-Arg11 (2 mM) or scrRIAD-Arg11 (2 mM) for 1 h followed by addition of PGI2 (50 nM) for 1 mine and then stimulated with collagen (5 mg/ml) for
4 min under stirring conditions. (Ai) representative aggregation traces. (Aii) Collated data of four independent experiments expressed as mean  SEM.  p < 0.01
compared to absence of PGI2; *p < 0.05 compared to PGI2 alone. (B) As in (A) except platelet ATP secretion was measured by the signal released by a
Luciferin-Luciferase reaction using a Chrono-log Lumi-aggregometer. (Bi) representative ATP secretion traces. (Bii) Collated data of four independent experiments
expressed as mean  SEM. p < 0.01 compared to absence of PGI2; *p < 0.05 compared to PGI2 alone. (C) Washed platelets (5  107/ml) were placed on
human serum (i) or collagen-coated coverslips (50 mg/ml) (ii–iv) for 60 min at 37°C in the absence (ii) or presence (ii) PGI2 (100 nM). In (iv) washed platelets were first
pre-treated with RIAD-Arg11 (2 mM) for 1 h followed by addition of PGI2 (100 nM). At the end of the incubation period, non-adherent platelets were removed by
washing with PBS. The remaining adherent platelets were fixed, permeabilized with 0.1% Triton, and stained for F-action with TRITC-conjugated phalloidin then
visualized with fluorescence microscope. Scale bar is 5 mm.
Frontiers in Pharmacology | www.frontiersin.org November 2015 | Volume 6 | Article 2665
Raslan et al. cAMP signaling in blood platelets
protein 2), WAVE-1 (Wiskott–Aldrich syndrome protein
verprolin homologous 1), MAP2 (microtubuleassociated protein
2), smAKAP (small-membrane AKAP) and neurobeachin.
Of those fifteen AKAPs we were able to verify the presence
of several by immunoblotting techniques. To the best of our
knowledge only two functional AKAPs have been identified
in platelets, small membrane AKAP (smAKAP) and moesin.
SmAKAP was identified in platelets and cardiomyocytes by using
chemical proteomics. This AKAP specifically targets PKA-I to
cellular membrane through myristoylation and palmitoylation
anchors (Burgers et al., 2012). Verification of the presence of
smAKAP by immunoblotting and its functional role is yet to
be determined in platelets. Using a combination of cAMP pull-
down, immunoblotting and kinase assays we reported recently
that moesin targets PKA-I into platelet lipid rafts where it can
phosphorylate its physiological substrate GPIbb (Raslan et al.,
2015). This phosphorylation event contributes to the inhibition
of platelet-driven thrombus formation to the adhesive protein
von Willebrand factor. This data identifies moesin as the first
functionally validated AKAP in platelets, but also indicate GPIbb
as the first PKA-I-specific substrate in platelets. Interestingly,
we observed multiple phosphoproteins in platelet lipid rafts
that were sensitive to the localisation of PKA-I suggesting that
these microdomains may focus PKA-I on several targets required
for regulation of platelet function by cAMP. These two studies
provide an insight into the potential compartmentalization of
cAMP signaling by AKAPs, although more work is required to
understand the composition and dynamics of AKAP-regulated
macromolecules in platelets.
PERSPECTIVE
The cAMP signaling pathway represents the most potent
endogenous system for the control of platelet activation through
its ability to modulate multiple platelet functions. However,
the molecular mechanisms by which cAMP/PKA signaling
controls individual platelet functions are unclear. Fundamental
to elucidating this issue is an improved understanding of
the organization and spatial resolution of the downstream
effectors of cAMP in platelets. Emerging data suggests that
compartmentalization of key cyclic nucleotide signaling
complexes may control aspects of platelet function as evident
by the identification of a localized PKG1b-IP3R1-IRAG-PDE5
complex that regulate calcium release in response to NO
(Wilson et al., 2008). The challenge for platelet biologists is
to determine whether this multi-protein complex model can
be extended to the cAMP pathway. The advances in both
transcriptomics and proteomics have now identified a number
of AKAPs that potentially provide spatial resolution and
specificity to PKA-mediated phosphorylation events. Our data
demonstrating differential localization of PKA-I and PKA-II
and compartmentalization of PKA-I by the AKAP moesin to
target a specific substrate provide proof of principle that the
AKAP hypothesis can be translated to platelets. Interestingly,
we have found that the catalytic subunit of PKA is constitutively
associated with RhoA (Aburima et al., 2013), PDE3A and
IP3R1 through AKAP-dependent mechanisms (unpublished),
suggesting the presence of numerous individual PKA-AKAP
complexes. Unfortunately, platelet research in this area is
hampered by an inability to apply conventional gene silencing
or overexpression technologies and therefore relies on the
identification of native complexes through protein purification.
As protein purification techniques become more sensitive, the
ability to identify and characterize native complexes increases
and may allow functional relevance to be established. Our data
with cell permeable disruptor peptides provide one approach to
address this issue. However, these peptides are limited in their
specificity and only allow resolution of isoform-specific signaling
and functional events. Future lines of investigation could involve
the identification of individual PKA-AKAP complexes and
the application of a new generation of peptide disruptors that
discriminate between individual PKA-AKAP complexes (Gold
et al., 2013). An important resource for the functional assessment
of AKAPs in platelets is genetically modified mice. In the
absence of standard molecular biology approaches, mice offer a
strategy for examining the role of specific PKA-AKAP complexes
on haemostasis and thrombosis in vivo. For example, mice
heterozygous for Neurobeachin, an established AKAP (Wang
et al., 2001), demonstrated altered PKA phosphorylation profile
and abnormal platelet dense granules (Nuytens et al., 2013).
Detailed examination of platelet sensitivity to cAMP of such mice
and their use in adoptive transfer protocols are likely to be key
tools for future evaluation of specific PKA-AKAP complexes in
the physiological control of platelet function.
The original AKAP hypothesis has now evolved beyond simple
anchoring of PKA signaling, with identification of numerous
other signaling moieties including phosphatases, PDEs and
other kinases coalescing into the complexes (Zaccolo, 2011;
Scott et al., 2013). Moreover, these multi-protein signaling
hubs are extremely dynamic in nature and have been shown to
be both tissue and substrate specific. This particular concept
has a specific relevance for platelets where cAMP signaling
needs to respond to physiological stimuli that promote platelet
activation. Indeed, it may be that the dynamic adjustment
of these complexes, in response to agents that promote
cAMP generation and platelet agonists, is what determines
the threshold for platelet activation and allows effective
haemostasis while preventing thrombosis. We believe that the
identification of platelet AKAPs through proteomics provides
the platform for new lines of investigation in establishing
the spatial and temporal organization of cAMP signaling
in platelets and how this intersects with platelet activatory
signaling.
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